P62 (Sqstm1) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
p62 (also known as SQSTM1 or Sequestosome-1) is a multifunctional scaffolding protein that serves as a selective autophagy receptor and signaling hub in neurons. p62-containing neurons represent a population of cells that rely heavily on autophagy for maintaining cellular homeostasis, particularly in the context of neurodegenerative diseases. p62 is unique among autophagy receptors because it directly binds to both ubiquitin chains on cargo and LC3 on the autophagosome membrane, facilitating the selective engulfment of damaged proteins and organelles for degradation. [1]
The p62 protein has emerged as a critical player in neurodegeneration due to its involvement in multiple pathogenic processes, including the formation of protein aggregates in Alzheimer's disease, Parkinson's disease, and ALS. p62 is found in neurofibrillary tangles in AD, Lewy bodies in PD, and TDP-43 inclusions in ALS, making it a key marker of cellular stress and dysfunction in neurodegenerative conditions. [2]
The SQSTM1 gene encodes the p62 protein, which is 440 amino acids in length and contains multiple functional domains that enable its diverse cellular functions. The N-terminal PB1 domain allows p62 to form oligomers and interact with other proteins, while the ZZ domain binds to receptor-interacting protein (RIP). The central region contains the microtubule-associated protein 1 light chain 3 (LC3)-interacting region (LIR) and the ubiquitin-binding domain (UBA), which are essential for p62's role in selective autophagy. [3]
The C-terminal region includes the KEAP1 interaction region (KIR), which allows p62 to sequester KEAP1 and activate the Nrf2 transcription factor, a master regulator of antioxidant response genes. This dual function as both an autophagy receptor and a signaling molecule makes p62 a central node in cellular proteostasis and stress response networks. [4]
p62 serves as a selective autophagy receptor by recognizing ubiquitinated cargo and targeting it for degradation through the autophagy-lysosome pathway. This process, known as selective autophagy, is particularly important in neurons due to their post-mitotic nature and high metabolic demands. Unlike other cells, neurons cannot dilute accumulated damaged proteins through cell division, making autophagy essential for their long-term survival. [5]
The mechanism of p62-mediated selective autophagy involves several steps. First, p62 binds to ubiquitinated protein aggregates, damaged mitochondria, or other cellular debris through its UBA domain. Second, p62 oligomerizes through its PB1 domain, forming large protein complexes that sequester the cargo. Third, p62 interacts with LC3 on the growing autophagosome membrane via its LIR motif. Finally, the p62-cargo complex is engulfed by the autophagosome and delivered to the lysosome for degradation. [6]
In neurons, p62-mediated autophagy is particularly important for degrading protein aggregates that accumulate in various neurodegenerative conditions. The inability to efficiently clear these aggregates leads to cellular toxicity and neuronal death. [7]
p62 is expressed in neurons throughout the brain, with particularly high levels in regions vulnerable to neurodegeneration, including the hippocampus, substantia nigra, and motor cortex. Within neurons, p62 localizes to the cytoplasm, where it associates with various organelles including the endoplasmic reticulum, mitochondria, and peroxisomes.
Under normal conditions, p62 levels are relatively low in healthy neurons, reflecting balanced rates of autophagy and protein turnover. However, in response to cellular stress or impaired autophagy, p62 accumulates dramatically, forming visible inclusions that are pathological hallmarks of neurodegenerative diseases.
In Alzheimer's disease, p62 is a key component of neurofibrillary tangles, where it colocalizes with hyperphosphorylated tau protein. The presence of p62 in tangles reflects the cell's attempt to degrade abnormal tau aggregates through autophagy. However, impaired autophagic-lysosomal function in AD neurons prevents efficient clearance, leading to p62 accumulation.
p62 also plays a role in AD through its interaction with the Nrf2 pathway. By sequestering KEAP1, p62 activates Nrf2 signaling, which promotes expression of antioxidant genes. This represents a compensatory neuroprotective response that is ultimately insufficient to prevent disease progression.
In Parkinson's disease, p62 is found in Lewy bodies, the characteristic protein inclusions that define sporadic PD. These inclusions contain alpha-synuclein along with various other proteins, including p62. p62's presence in Lewy bodies indicates involvement in the failed attempt to clear aggregated alpha-synuclein through autophagy.
Additionally, p62 plays a critical role in mitophagy, the selective autophagy of damaged mitochondria. In PD, mitochondrial dysfunction is a central pathogenic mechanism, and p62 helps target impaired mitochondria for degradation. Genetic variants in the SQSTM1 gene have been associated with increased PD risk, further supporting its importance in disease pathogenesis.
In ALS, p62 inclusions are commonly observed in motor neurons, often colocalizing with TDP-43 aggregates. These inclusions represent a cellular response to proteostatic stress and impaired autophagy. Notably, p62 mutations cause familial ALS, directly linking p62 dysfunction to motor neuron disease pathogenesis.
p62 inclusions are also found in other neurodegenerative conditions, including frontotemporal dementia, Huntington's disease, and Creutzfeldt-Jakob disease. This widespread involvement reflects the fundamental role of p62 in cellular proteostasis and the universal importance of autophagy in neuronal health.
The central role of p62 in neurodegeneration makes it an attractive therapeutic target. Several strategies are being explored to enhance p62-mediated autophagy and improve clearance of toxic protein aggregates. These include:
Autophagy enhancement: Small molecules that activate autophagy through mTOR-independent pathways could boost p62-mediated clearance of protein aggregates. Natural compounds like rapamycin and spermidine have shown promise in preclinical models.
p62 expression modulation: Strategies to increase p62 expression or enhance its functional activity could improve autophagy capacity in neurons. Gene therapy approaches to deliver functional p62 are under investigation.
Nrf2 pathway activation: By activating the p62-KEAP1-Nrf2 axis, it may be possible to enhance antioxidant defenses and protect neurons from oxidative stress. Pharmacological Nrf2 activators are being tested in various neurodegenerative models.
Future research on p62 in neurodegeneration should address several key questions. First, the precise mechanisms linking p62 dysfunction to neuronal death need clarification. Second, the relationship between p62 genetic variants and disease risk requires further investigation. Third, the development of p62-targeted therapeutics demands a better understanding of p62's normal functions in neurons.
Single-cell sequencing and proteomic approaches will help characterize p62-expressing neuronal populations and identify downstream effectors. Additionally, patient-derived iPSC models will enable study of p62 function in human neurons carrying disease-causing mutations.
p62 (SQSTM1) is a multifunctional autophagy receptor and signaling molecule that plays critical roles in neuronal proteostasis and stress responses. In neurodegenerative diseases, p62 accumulates in characteristic protein inclusions, reflecting both the cell's attempt to clear toxic aggregates and the dysfunction of autophagic degradation. Understanding p62 biology provides insights into disease mechanisms and reveals potential therapeutic targets for conditions including Alzheimer's disease, Parkinson's disease, and ALS.
The study of P62 (Sqstm1) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Komatsu M et al. p62 in neurodegeneration (2018). 2018. ↩︎
Lee Y et al. p62 and Nrf2 signaling (2020). 2020. ↩︎
Katsuragi Y et al. p62 bodies in neurodegeneration (2015). 2015. ↩︎
Galloway CA et al. p62 in mitophagy and PD (2019). 2019. ↩︎
Chen W et al. p62 and tau pathology (2020). 2020. ↩︎
Bjorkoy G et al. p62 inclusions in disease (2009). 2009. ↩︎
Duran A et al. p62 function in autophagy (2011). 2011. ↩︎